ProMIS Neurosciences Business Summary

ProMIS Neurosciences Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company that operates a research-driven business model focused on the discovery and development of precision antibody therapeutics and vaccines for neurodegenerative disorders. The company generates revenue primarily through strategic licensing agreements, milestone payments, and potential future royalties derived from its proprietary drug candidates, though it is currently funded through institutional capital raises. Its operations are segmented by disease indication, targeting toxic misfolded proteins associated with Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). ProMIS leverages a proprietary computational discovery platform—utilizing ProMIS™ and Collective Coordinates algorithms—to identify Disease Specific Epitopes (DSEs), enabling the development of antibodies that selectively target toxic oligomers while sparing healthy protein variants. Positioned as a precision-medicine specialist, ProMIS competes with industry players such as Denali Therapeutics, Amylyx Pharmaceuticals, Anavex Life Sciences, and Alzheon, distinguishing itself through its high-selectivity approach designed to enhance safety and efficacy over broader-spectrum amyloid-targeting therapies. The company was co-founded by Chief Scientific Officer Dr. Neil Cashman, a preeminent neurologist and professor at the University of British Columbia recognized for his pioneering work in protein misfolding and ALS. The executive leadership is led by CEO Neil Warma, a seasoned biotech veteran with a pedigree including leadership roles at Genexine, I-Mab Biopharma, and Novartis. Supporting the strategic direction is Executive Chairman Eugene Williams, a former Senior Vice President at Genzyme with extensive experience in drug commercialization and deal-making. ProMIS is backed by a robust roster of institutional investors, recently securing up to $175 million in PIPE financing in early 2026 co-led by Janus Henderson and Ally Bridge Group, with participation from Wellington Management and Deep Track Capital. The Board of Directors features prominent industry experts, including Slanix Paul Alex of Ally Bridge Group and Josh Mandel-Brehm, President and CEO of CAMP4 Therapeutics.